Figures published by NHS Improvement shows that NHS provider sector has generated a year-to-date deficit of £886 million, with the sector forecasting a year-end deficit of £873m. According to the regulator, NHS providers are “experiencing one of the most challenging winters on record” due to a huge increase in the demand for urgent and emergency
Digital heart scanning software created by HeartFlow that can assess the cause of chest pain, has been recommended for use on the NHS, with the potential of saving the health service millions. England and Wales’ cost effectiveness watchdog NICE says the HeartFlowFFRCT could replace currently used invasive procedures with software which produces a 3-D digital
In a study of mice and monkeys, NIH funded researchers showed that they could prevent and reverse some of the brain injury caused by the toxic form of a protein called tau. The results, published in Science Translational Medicine, suggest that the study of compounds, called tau antisense oligonucleotides, that are genetically engineered to block
The British Heart Foundation has estimated that approximately 620,000 people in the UK are potentially carrying a faulty gene that puts them at high risk sudden death, but the foundation warns majority of carriers are unaware. The charity also noted that an accurate figure could be much higher due to under diagnosis and undiscovered faulty
Roche’s Tecentriq has scored another positive opinion. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently accepted the immunotherapy drug into the Early Access to Medicines Scheme (EAMS) for the treatment advanced bladder cancer. The decision means that patients suffering from bladder cancer could have access to the drug while it awaits decision from
AstraZeneca has expanded a late-stage trial that assess a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy. The Phase III MYSTIC trial was originally designed to assess the benefit of durvalumab monotherapy and a combination of durvalumab
Allergan has stepped into the field of Parkinson’s disease with an option to acquire US-based neurodegenerative research group Lysosomal Therapeutics (LTI). LTI-291, LTI’s lead programme, is designed to stimulate the activity of glucocerebrosidase (GCase) in the brain, which is reduced in many lysosomal storage diseases because of mutations in the GBA1 gene.
The human body has a built-in army to help combat against disease, the immune system. In addition to fighting off bacteria and viruses it can also help combat tumours. That’s why researchers are attempting to rally these cells to treat cancer, leading to some significant advances being made over previous years.
A drug that ‘reinvigorates the immune system’ can extend the lives of lung cancer patients with reduced side effects, according to preliminary results from a late stage clinical trial. “This is another great example of how research into the immune system can deliver powerful new treatments” – Professor Peter Johnson, Cancer Research UK. Patients with
Chief executive of NHS England, Simon Stevens, has unveiled the first fraction of hospitals that will benefit from a major national investment in NHS radiotherapy machines. Fifteen hospitals in areas where there is greatest need have now been selected to receive new LINAC linear (accelerator) machines, as part of a £130-million investment in radiotherapy